KYTXKyverna TherapeuticsRunning, no new patients
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
Multiple Sclerosis, Primary Progressive · Multiple Sclerosis, Secondary Progressive · Multiple Sclerosis · MS
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 120 (planned)
- Started
- Sep 20, 2024
- Main results expected
- Apr 2027
- Fully finished
- Jan 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To evaluate efficacy of KYV-101
Measured over: at least 12 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06384976 · record last updated 2025-01-13 · checked 2026-11-09 15:47 UTC